Happy Mothers Day to the mom's here! ;)
frrol... I fully agree with this statement:
In the meantime, management is moving forward doing things they can with limited capital. Hats off to them for that. They are not giving up.
Without knowing details about company discussions/negotiations/signed term sheet/s we simply don't know what the actual catalysts are/were.
All we can do is speculate. We can't definitively say what is or isn't a catalyst regarding the ongoing discussions/negotiations.
An announcement of a signed deal is the only thing I see that will move share price
substantially and hold. There is no guarantee of a deal. However, I believe the company is putting forth great effort to get one. I wish the company success for my investment here and for future patients to have access to new drugs. I see tremendous potential value in Brilacidin.
Hopefully, the drug that is being manufactured will be put to use soon in a Brilacidin ph3 OM trial.
In Reply to 'frrol'
No. Just like the FDA meeting wasn't a deal catalyst, nor the FDA minutes, nor the EMA meeting. There's no catalyst that we are "just waiting for", as much as you want to believe that and keep coming up with new ones, one after the other. The only catalyst is a partner saying they want to license. And this is what management is trying to do. In the meantime, management is moving forward doing things they can with limited capital. Hats off to them for that. They are not giving up.
(The catalyst for our previous term sheet was quite clearly the BTD, which would have been very meaningful and valuable to a partner. The pharma was obviously not sure it would be granted, nor our management for that matter though they had to try; you'll note they heavily backed off on touting possible BTD after final B-OM results were in, only saying they would apply in the 10Q's.)